@article {69560, title = {Activity-dependent synapse elimination requires caspase-3 activation}, journal = {eLife}, year = {2025}, month = {2025 Jul 10}, abstract = {

During brain development, synapses are initially formed in excess and are later eliminated in an activity-dependent manner, with weak synapses being preferentially removed. Previous studies identified glia as mediators of synapse removal, but it is unclear how glia specifically target weak synapses. Here we show that, in the developing mouse visual pathway, inhibiting synaptic transmission induces postsynaptic activation of caspase-3. Caspase-3 is essential for synapse elimination driven by both spontaneous and experience-dependent neural activity. Synapse weakening-induced caspase-3 activation determines the specificity of synapse elimination mediated by microglia but not astrocytes. Furthermore, in a mouse model of Alzheimer{\textquoteright}s disease, caspase-3 deficiency protects against synapse loss induced by amyloid-β deposition. Our results reveal caspase-3 activation as a key step in activity-dependent synapse elimination during development and synapse loss in neurodegeneration.

bioRxiv preprint:\ https://doi.org/10.1101/2024.08.02.606316

}, doi = {10.7554/eLife.101779.2}, url = {https://doi.org/10.7554/eLife.101779.2}, author = {Yu, Zhou and Gutu, Andrian and Kim, Namsoo and O{\textquoteright}Shea, Erin K.} } @article {49222, title = {Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing-bisphosphonates.}, journal = {eLife}, volume = {7}, year = {2018}, month = {2018 May 10}, abstract = {

Nitrogen-containing-bisphosphonates (N-BPs) are a class of drugs widely prescribed to treat osteoporosis and other bone-related diseases. Although previous studies have established that N-BPs function by inhibiting the mevalonate pathway in osteoclasts, the mechanism by which N-BPs enter the cytosol from the extracellular space to reach their molecular target is not understood. Here we implemented a CRISPRi-mediated genome-wide screen and identified (solute carrier family 37 member A3) as a gene required for the action of N-BPs in mammalian cells. We observed that SLC37A3 forms a complex with ATRAID (all-trans retinoic acid-induced differentiation factor), a previously identified genetic target of N-BPs. SLC37A3 and ATRAID localize to lysosomes and are required for releasing N-BP molecules that have trafficked to lysosomes through fluid-phase endocytosis into the cytosol. Our results elucidate the route by which N-BPs are delivered to their molecular target, addressing a key aspect of the mechanism of action of N-BPs that may have significant clinical relevance.

}, issn = {2050-084X}, doi = {10.7554/eLife.36620}, author = {Yu, Zhou and Surface, Lauren E and Park, Chong Yon and Horlbeck, Max A and Wyant, Gregory A and Abu-Remaileh, Monther and Peterson, Timothy R and Sabatini, David M and Weissman, Jonathan S and O{\textquoteright}Shea, Erin K} }